NEW YORK (360Dx) – A team led by researchers from IBM have identified a plasma protein signature that predicts cerebrospinal fluid (CSF) levels of the Alzheimer's disease marker amyloid-β42.

Part of a growing body of research into blood-based biomarkers for Alzheimer's disease, the study, published this week in Nature Scientific Reports, adds to the evidence that blood tests could prove useful alternatives to the CSF and PET imaging-based tests currently used to assess brain amyloid levels.